Results 151 to 160 of about 53,202 (260)
Endoscopic small bowel therapies for type 2 diabetes
Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1296-1306, October 2026.Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel +4 more
wiley +1 more source
Tracking Bone Loss in GLP-1RA Therapy: The Potential of the Deoxypyridinoline Urine Test. [PDF]
Diagnostics (Basel)Margoni A, Basdra EK, Papavassiliou AG.
europepmc +1 more source
Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review
Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1308-1317, October 2026.Abstract Humans have a primitive defense mechanism called metabolic adaptation that slows voluntary weight loss. It works by downregulating hormones that reduce food intake and by lowering the metabolic rate. Second‐generation GLP‐1 receptor agonists, such as semaglutide or tirzepatide, promote weight loss by targeting this hormonal system to control ...
Ken Fujioka
wiley +1 more source
Patient‐Reported Continuity of GLP‐1 Receptor Agonist Therapy
Obesity Science &Practice, Volume 12, Issue 5, October 2026.ABSTRACT Objective Use of GLP‐1 receptor agonists is associated with significant weight loss in many individuals. Discontinuation is associated with weight regain. Patients' experience with this is not well characterized. This study describes the patient experience of continuity of care.
You Chen +9 more
wiley +1 more source
GLP-1RA Use and the Risk of Heart Failure in Patients With Diabetes: Association or Causation? [PDF]
CirculationInoue K, Kazi DS.
europepmc +1 more source
Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study. [PDF]
BMC Pulm MedWu Y +9 more
europepmc +1 more source
Obesity Science &Practice, Volume 12, Issue 5, October 2026.ABSTRACT Background Food noise is a term that has recently emerged in the media, social media, and public discourse to describe people's experiences around food‐related thoughts. Despite recent efforts to define and measure food noise and the abundance of online content on the topic, the proportion of US adults who believe they experience it remains ...
Daisuke Hayashi, Travis D. Masterson
wiley +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.ABSTRACT Type 2 diabetes mellitus (T2DM) has increasingly been identified as a risk factor for sensorineural hearing loss, whereas the association between different antidiabetic therapies and hearing thresholds remains poorly characterized. This retrospective observational study evaluated 240 patients with T2DM and 105 normoglycemic controls who ...
Francesco Martines +8 more
wiley +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.ABSTRACT Incretin effect helps in regulating glucose homeostasis and maintaining glycaemic control within the human body. This effect is achieved by the two naturally occurring incretin hormones: glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1).
Nora H. J. Alharbi
wiley +1 more source
Acta Psychiatrica Scandinavica, Volume 154, Issue 4, Page 305-312, October 2026.ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale +5 more
wiley +1 more source